Actavis, Inc. is a global, integrated specialty pharmaceutical company focused on developing, manufacturing and distributing generic, brand and biosimilar products. It develops, manufactures and market generic, branded generic, legacy brands and Over... More
AURO LAB. ACTAVIS |
EQUITY SHARE DATA | |||||
---|---|---|---|---|---|
AURO LAB. Mar-23 |
ACTAVIS Dec-18 |
AURO LAB./ ACTAVIS |
5-Yr Chart Click to enlarge
|
||
High | Rs | 116 | 16,120 | - | |
Low | Rs | 53 | 10,814 | - | |
Sales per share (Unadj.) | Rs | 84.9 | 3,954.3 | - | |
Earnings per share (Unadj.) | Rs | 3.9 | -1,273.7 | - | |
Cash flow per share (Unadj.) | Rs | 5.6 | 416.7 | - | |
Dividends per share (Unadj.) | Rs | 0 | 0 | - | |
Avg Dividend yield | % | 0 | 0 | - | |
Book value per share (Unadj.) | Rs | 54.9 | 16,309.8 | - | |
Shares outstanding (eoy) | m | 6.23 | 332.60 | - | |
Bonus / Rights / Conversions | 0 | 0 | - | ||
Price / Sales ratio | x | 1.0 | 3.4 | 29.1% | |
Avg P/E ratio | x | 21.5 | -10.6 | -203.3% | |
P/CF ratio (eoy) | x | 14.9 | 32.3 | 46.2% | |
Price / Book Value ratio | x | 1.5 | 0.8 | 185.9% | |
Dividend payout | % | 0 | 0 | - | |
Avg Mkt Cap | Rs m | 525 | 4,479,145 | 0.0% | |
No. of employees | `000 | NA | 16.9 | 0.0% | |
Total wages/salary | Rs m | 38 | 0 | - | |
Avg. sales/employee | Rs Th | 0 | 77,823.4 | - | |
Avg. wages/employee | Rs Th | 0 | 0 | - | |
Avg. net profit/employee | Rs Th | 0 | -25,066.9 | - |
INCOME DATA | |||||
---|---|---|---|---|---|
Net Sales | Rs m | 529 | 1,315,215 | 0.0% | |
Other income | Rs m | 9 | 25,151 | 0.0% | |
Total revenues | Rs m | 538 | 1,340,366 | 0.0% | |
Gross profit | Rs m | 44 | 34,465 | 0.1% | |
Depreciation | Rs m | 11 | 562,226 | 0.0% | |
Interest | Rs m | 8 | 75,895 | 0.0% | |
Profit before tax | Rs m | 34 | -578,505 | -0.0% | |
Minority Interest | Rs m | 0 | 0 | - | |
Prior Period Items | Rs m | 0 | 0 | - | |
Extraordinary Inc (Exp) | Rs m | 0 | 147,542 | 0.0% | |
Tax | Rs m | 10 | -7,331 | -0.1% | |
Profit after tax | Rs m | 24 | -423,631 | -0.0% | |
Gross profit margin | % | 8.3 | 2.6 | 316.9% | |
Effective tax rate | % | 29.1 | 1.3 | 2,298.3% | |
Net profit margin | % | 4.6 | -32.2 | -14.3% |
BALANCE SHEET DATA | |||||
---|---|---|---|---|---|
Current assets | Rs m | 354 | 539,432 | 0.1% | |
Current liabilities | Rs m | 181 | 477,200 | 0.0% | |
Net working cap to sales | % | 32.6 | 4.7 | 689.0% | |
Current ratio | x | 2.0 | 1.1 | 172.6% | |
Inventory Days | Days | 2 | 20 | 11.8% | |
Debtors Days | Days | 85,599 | 66 | 129,091.3% | |
Net fixed assets | Rs m | 206 | 148,875 | 0.1% | |
Share capital | Rs m | 62 | 0 | - | |
Net worth | Rs m | 342 | 5,424,647 | 0.0% | |
Long term debt | Rs m | 20 | 1,910,215 | 0.0% | |
Total assets | Rs m | 560 | 8,479,958 | 0.0% | |
Interest coverage | x | 5.2 | -6.6 | -79.0% | |
Debt to equity ratio | x | 0.1 | 0.4 | 16.7% | |
Sales to assets ratio | x | 0.9 | 0.2 | 609.1% | |
Return on assets | % | 5.8 | -4.1 | -141.8% | |
Return on equity | % | 7.1 | -7.8 | -91.4% | |
Return on capital | % | 11.8 | -4.8 | -243.0% |
CASH FLOW | |||||
---|---|---|---|---|---|
From Operations | Rs m | 33 | 469,877 | 0.0% | |
From Investments | Rs m | -51 | 258,136 | -0.0% | |
From Financial Activity | Rs m | -82 | -806,449 | 0.0% | |
Net Cashflow | Rs m | -100 | -78,045 | 0.1% |
Compare AURO LAB. With: ADCOCK INGRAM (S. Africa) MYLAN (US) TEVA PHARMA (Israel)
Compare AURO LAB. With: SAMRAT PHARMA NORRIS MEDICINES ISHITA DRUGS GENNEX LAB. IOL CHEMICALS & PHARM.
After opening the day lower, Indian share continued the momentum as the session progressed and ended the day lower.